RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
The conversation is about overcoming fear of finasteride/dutasteride for hair loss treatment. Users suggest starting with a small supply, noting side effects are rare and reversible, and emphasize personal comfort and confidence.
The conversation is about using tretinoin with minoxidil for hair loss treatment. The user is seeking advice on usage frequency and results after adding tretinoin to their regimen.
The conversation is about switching from finasteride to dutasteride for hair loss treatment. Users shared mixed experiences with side effects and effectiveness, with some preferring to stick with finasteride if it's working.
The post and conversation discuss KX-826 (pyrilutamide) for hair loss treatment, with positive remarks about its advertising and authenticity in China. The user changed their perspective after further research and seeing genuine advertising.
Users discuss switching from finasteride to dutasteride for hair loss treatment. Some report better results with dutasteride, including hair regrowth and stabilization.
User shared a 3-month progress update on hair loss treatment using finasteride and minoxidil. They experienced initial shedding, thicker hair growth, and facial breakouts likely due to hormone changes.
A user is comparing Capillus Ultra and Capillus ONE for hair loss treatment, questioning if the number of diodes matters. Another user suggests the OMG helmet as the only worthwhile option.
The conversation is about adding dermarolling to a hair loss treatment routine. The user seeks recommendations for dermarollers, stamps, or pens, emphasizing the importance of quality and proper cleaning.
The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.